Results 131 to 140 of about 1,052,124 (265)

Constraining the low-mass end of the initial mass function with gravitational lensing

, 2010
Ignacio Ferreras, Prasenjit Saha, Dominik Leier, F. Courbin, E. Falco   +4 more
openalex   +1 more source

Where, How, and How Much? A Multicenter Cohort Study of the Relationship Across Lupus Decision‐Aid Modality, Place of Administration, Interruption and Viewing Completeness, and Patient‐Reported Outcomes

Arthritis Care &Research, EarlyView.
Objective We assessed whether shared decision‐making (SDM) and patient acceptability, feasibility, and overall satisfaction with a computerized patient decision aid (PtDA) for patients with systemic lupus erythematosus (SLE) differs by PtDA setting, modality, and the viewing experience. Methods Patients with SLE were invited to view a self‐administered
Jasvinder A. Singh, Mark Beasley, Larry R. Hearld, for the Implementing Decision‐Aid for Lupus in Clinics (IDEAL) Consortium, Winn Chatham, Jasvinder Singh, Sonali Narain, Narender Annapureddy, Diane Kamen, Kimberly Trotter, Vikas Majithia, Cathy Ching, Zineb Aouhab, Swamy Venturupalli, Rosalind Ramsey‐Goldman, Alfred Kim, Maureen McMahon, Sam Lim, Kalpana Bhairavarasu, Alexa Meara, Kenneth Kalunian   +20 more
wiley   +1 more source

EVIDENCE FOR TWO DISTINCT STELLAR INITIAL MASS FUNCTIONS: PROBING FOR CLUES TO THE DICHOTOMY [PDF]

, 2014
Dennis Zaritsky, Janet E. Colucci, Peter Pessev, Rebecca Bernstein, Rupali Chandar   +4 more
openalex   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Membrane-based nanopurification for plastic recycling. [PDF]

Commun Chem
Laviolette JP, Eslami A, Doucet J.
europepmc   +1 more source

Development of a Personalized Visualization and Analysis Tool to Improve Clinical Care in Complex Multisystem Diseases With Application to Scleroderma

Arthritis Care &Research, EarlyView.
Objective In complex diseases, it is challenging to assess a patient's disease state, trajectory, treatment exposures, and risk of multiple outcomes simultaneously, efficiently, and at the point of care. Methods We developed an interactive patient‐level data visualization and analysis tool (VAT) that automates illustration of the trajectory of a ...
Ji Soo Kim, John Scott, Lauren Fisher, Lauren N. Smith, Willie Stewart, Adrianne Woods, Rob Smithwright, Diane Koher, Parastoo Aslanbeik, Aalok B. Shah, Brad Tibbils, Samantha I. Pitts, Ayse P. Gurses, Yushi Yang, Ana‐Maria Orbai, Antony Rosen, Laura K. Hummers, Scott L. Zeger, Ami A. Shah   +18 more
wiley   +1 more source

Changes to physical function and body composition during the first 2 years of polymyalgia rheumatica. [PDF]

Rheumatology (Oxford)
Leung JL, De Ross B, Gianoudis J, Deeble N, Yang V, Liew DFL, Daly RM, Buchanan RRC, Owen CE.   +8 more
europepmc   +1 more source

Exploring the spatially resolved initial mass function in SAMI star-forming galaxies

Diego Salvador, Andrew Hopkins, M. S. Owers, Themiya Nanayakkara, S. M. Croom   +4 more
openalex   +1 more source

The Magellanic Bridge Cluster NGC 796: Deep Optical AO Imaging Reveals the Stellar Content and Initial Mass Function of a Massive Open Cluster [PDF]

, 2018
Venu M. Kalari, Giovanni Carraro, Christopher J Evans, Mónica Rubio, Venu M. Kalari, Giovanni Carraro, Christopher J Evans, Mónica Rubio   +7 more
openalex   +1 more source

Improvements in Health‐Related Quality of Life with Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post‐hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, Accepted Article.
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source